### ðŸ«€ Valvular Heart Disease: Anticoagulation for Mechanical Heart Valve During Pregnancy

#### âœ… True Statements
1. In **pregnant patients with a mechanical heart valve**, the preferred anticoagulation strategy is to switch from **warfarin** to **lowâ€‘molecularâ€‘weight heparin (LMWH)** during gestational weeksâ€¯6â€¯throughâ€¯12, resume **warfarin** until weekâ€¯36, and then use **intravenous unfractionated heparin (UFH)** for delivery.
2. **Warfarin** administration in the **first trimester of pregnancy** can cause **warfarin embryopathy**, and the teratogenic risk is greatest when the maternal daily dose exceedsâ€¯**5â€¯mg**.
3. Continuous use of **LMWH** or **UFH** during pregnancy is safer for the fetus than **warfarin** but is associated with a **higher risk of mechanical prosthetic valve thrombosis**.
4. **Direct oral anticoagulants (DOACs)** such as **apixaban** are **contraindicated** in patients with **mechanical heart valves** and have insufficient safety data for use during pregnancy.
5. Pregnant patients with a mechanical valve who enter **preterm labor while receiving warfarin** require **cesarean delivery** because warfarin crosses the placenta and increases the risk of **fetal intracranial hemorrhage** with vaginal delivery.

#### ðŸ’¬ Extra
1. This regimen balances maternal protection against valve thrombosis with fetal safety: weeksâ€¯6â€“12 encompass organogenesis, and withdrawing warfarin before delivery minimizes neonatal bleeding risk.
2. Warfarin embryopathy classically causes nasal and skeletal abnormalities; risk rises sharply above the 5â€¯mg/day dose threshold.
3. LMWH and UFH do not cross the placenta but must be monitored closely (antiâ€‘Xa levels or activated partial thromboplastin time) to ensure adequate anticoagulation.
4. Trials such as REâ€‘ALIGN showed increased thrombosis with DOACs in mechanical valves, and all DOACs cross the placenta to some extent.
5. Warfarinâ€™s placental transfer creates a bleeding hazard during the mechanical stresses of vaginal delivery, so cesarean section is recommended if labor begins while the mother is anticoagulated.

#### ðŸ”· Tags
#Cardiology #ValvularHeartDisease #MechanicalValve #Pregnancy #CardioObstetrics #AmbulatoryCare

#### ðŸ“™ Reference
Lindley KJ, Bairey Merz CN, Davis MB, etâ€¯al; American College of Cardiology Cardiovascular Disease in Women Committee and the Cardioâ€‘Obstetrics Work Group. **Contraception and reproductive planning for women with cardiovascular disease: JACC Focus Seminarâ€¯5/5.** *Journal of the American College of Cardiology*. 2021;77:1823â€‘1834. PMID:â€¯33832608â€ƒdoi:10.1016/j.jacc.2021.02.025

#### ðŸ†” Question ID
CVMCQ24049

#### ðŸ•’ Last Updated
Februaryâ€¯2025

---

#### ðŸ“– Related Text
Cardiovascular Medicine â€” Pregnancy and Cardiovascular Disease, Anticoagulation Therapy During Pregnancy

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Pregnancy** induces a **hypercoagulable state**, so pregnant individuals who require chronic anticoagulation need carefully monitored therapy.
2. **Prepregnancy counseling** is recommended for women who will need **longâ€‘term anticoagulation** during pregnancy so they can make informed choices about drug selection and maternal versus fetal risk.
3. **Warfarin**, **unfractionated heparin**, and **lowâ€‘molecularâ€‘weight heparin** can each be used during pregnancy when dosages are adjusted to achieve therapeutic targets.
4. **Warfarin** is **discontinued before delivery** to prevent **fetal intracranial hemorrhage** if spontaneous labor occurs.
5. Pregnant patients with a **mechanical valve prosthesis** should be managed by a **multidisciplinary cardioâ€‘obstetrics team** and should undergo **frequent anticoagulation monitoring** throughout pregnancy.
6. When **lowâ€‘molecularâ€‘weight heparin** is prescribed for a pregnant patient with a mechanical heart valve, dosing must be **adjusted by antiâ€‘Xa levels** to ensure adequate anticoagulation.
7. Women who become pregnant while taking a **direct oral anticoagulant** should switch promptly to **heparin or warfarin** because safety data on DOACs in pregnancy are limited.
8. For **venous thromboembolism** prophylaxis during pregnancy, **weightâ€‘based lowâ€‘molecularâ€‘weight heparin** or **intravenous/subcutaneous unfractionated heparin** targeting an **activated partial thromboplastin time (aPTT) twice control** is recommended from **weekâ€¯6 until delivery**.
9. In **nonvalvular atrial fibrillation**, women who can maintain a therapeutic **international normalized ratio (INR)** with **â‰¤5â€¯mg/day of warfarin** may continue warfarin during **weeksâ€¯6â€‘12 of gestation**; otherwise, **UFH** or **weightâ€‘based LMWH** are alternatives.
10. During **weeksâ€¯13â€‘37** of pregnancy, patients with **nonvalvular atrial fibrillation** may receive **subcutaneous UFH**, **weightâ€‘based LMWH**, or **therapeuticâ€‘INR warfarin**.
11. In **nonvalvular atrial fibrillation**, **intravenous UFH** (aPTTâ€¯2â€¯Ã—â€¯control) is the anticoagulant of choice from **weekâ€¯37 to term**.
12. For pregnant patients with a **mechanical heart valve** whose daily warfarin dose is **â‰¤5â€¯mg**, **continuing warfarin** during **weeksâ€¯6â€‘12** carries a **Classâ€¯2a** recommendation.
13. If the required **warfarin dose exceeds 5â€¯mg/day** in a pregnant patient with a mechanical valve, **intravenous UFH** or **antiâ€‘factorâ€¯Xaâ€“adjusted LMWH** are preferred during **weeksâ€¯6â€‘12**.
14. From **weeksâ€¯13â€‘37** of gestation, patients with a **mechanical valve prosthesis** should receive **therapeuticâ€‘INR warfarin**.
15. During **weekâ€¯37 to term**, **intravenous UFH** targeting an **aPTT twice control** is recommended for patients with a **mechanical valve prosthesis**.

#### ðŸ’¬ Extra
1. Increased levels of clotting factors (VII, VIII, X, and fibrinogen) and reduced proteinâ€¯S activity contribute to pregnancyâ€‘related hypercoagulability.
2. Counseling covers the teratogenicity of warfarin, thrombosis risk of heparinâ€‘based regimens, and delivery planning.
3. Target international normalized ratio (INR) for warfarin is typically 2.5â€“3.5 for mechanical aortic valves, while antiâ€‘Xa targets for LMWH are 1.0â€“1.2â€¯U/mL 4â€‘6â€¯h postâ€‘dose.
4. Switching to UFH or planned cesarean ensures minimal fetal exposure to warfarin during labor and delivery.
5. Disciplines involved include cardiology, maternalâ€‘fetal medicine, hematology, and anesthesiology.
6. Standard weightâ€‘based LMWH dosing may underâ€‘anticoagulate because of the increased renal clearance and volume of distribution in pregnancy.
7. Because DOACs lack reversal agents suitable for pregnancy and cross the placenta, guideline committees advise against their use.
8. Weightâ€‘based LMWH dosing typically uses the patientâ€™s pregnancyâ€‘adjusted weight and aims for antiâ€‘factorâ€¯Xa levels of 0.8â€‘1.2â€¯U/mL 4â€‘6â€¯h postâ€‘dose.
9. The **Classâ€¯2a** and **2b** designations reflect guideline strength of recommendation, with **Classâ€¯2a** indicating moderate benefit and **Classâ€¯2b** indicating weaker evidence.
10. Switching to UFH near delivery allows rapid reversal of anticoagulation if emergent cesarean section is required.

#### ðŸ”· Tags
#Cardiology #Pregnancy #MechanicalValve #Anticoagulation #CardioObstetrics #Hypercoagulability #PrepregnancyCounseling

---

#### ðŸ“Š Anticoagulation Regimens During Pregnancy (HTML with Footnotes)

<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse;width:100%;">
  <caption style="caption-side:top;font-weight:bold;text-align:left;margin-bottom:8px;">Anticoagulation Regimens During Pregnancy</caption>
  <thead>
    <tr>
      <th style="text-align:left;">Weeks of Gestation</th>
      <th style="text-align:left;">Recommended Regimen</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="2" style="background:#f2f2f2;"><strong>Venous Thromboembolism</strong></td>
    </tr>
    <tr>
      <td>Week 6 to term</td>
      <td>
        <ul>
          <li>Weight-based low-molecular-weight heparin (LMWH)</li>
          <li>Unfractionated heparin (UFH), intravenous (IV) or subcutaneous (SQ); activated partial thromboplastin time (aPTT) 2 Ã— control</li>
        </ul>
      </td>
    </tr>

    <tr>
      <td colspan="2" style="background:#f2f2f2;"><strong>Nonvalvular Atrial Fibrillation</strong></td>
    </tr>
    <tr>
      <td>Weeks 6â€“12</td>
      <td>
        <ul>
          <li>Warfarin (if dose to attain therapeutic international normalized ratio [INR] â‰¤ 5 mg)</li>
          <li>UFH (IV or SQ; aPTT 2 Ã— control)</li>
          <li>Weight-based LMWH</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Weeks 13â€“37</td>
      <td>
        <ul>
          <li>UFH (SQ; aPTT 2 Ã— control)</li>
          <li>Weight-based LMWH</li>
          <li>Warfarin (therapeutic INR)</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Week 37 to term</td>
      <td>UFH (IV; aPTT 2 Ã— control)</td>
    </tr>

    <tr>
      <td colspan="2" style="background:#f2f2f2;"><strong>Mechanical Valve Prosthesis</strong></td>
    </tr>
    <tr>
      <td>Weeks 6â€“12</td>
      <td>
        <p><em>If warfarin daily dose â‰¤ 5 mg for therapeutic INR:</em></p>
        <ul>
          <li>Continue warfarin (class 2a recommendation)</li>
          <li>UFH (IV; aPTT 2 Ã— control) (class 2b recommendation)</li>
          <li>Antiâ€“factor Xaâ€“adjusted LMWH (class 2b recommendation)</li>
        </ul>
        <p><em>If warfarin daily dose > 5 mg for therapeutic INR:</em></p>
        <ul>
          <li>UFH (IV; aPTT 2 Ã— control) (class 2a recommendation)</li>
          <li>Antiâ€“factor Xaâ€“adjusted LMWH (class 2a recommendation)</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>Weeks 13â€“37</td>
      <td>Warfarin (therapeutic INR)</td>
    </tr>
    <tr>
      <td>Week 37 to term</td>
      <td>UFH (IV; aPTT 2 Ã— control)</td>
    </tr>
  </tbody>
</table>

<p style="margin-top:1em;"><strong>Abbreviations:</strong> aPTT = activated partial thromboplastin time; IV = intravenous; LMWH = low-molecular-weight heparin; SQ = subcutaneous; UFH = unfractionated heparin.</p>

<p><strong>References:</strong></p>
<ul>
  <li>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72â€“e227. <a href="https://doi.org/10.1161/CIR.0000000000000923">PMID: 33332150</a></li>
  <li>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317â€“3359. <a href="https://doi.org/10.1182/bloodadvances.2018024802">PMID: 30482767</a></li>
  <li>Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121â€“1201. <a href="https://doi.org/10.1016/j.chest.2018.07.040">PMID: 30144419</a></li>
</ul>